AN2 Therapeutics Inc. (ANTX)

1.11

-0.03 (-2.63%)

At close: Mar 03, 2025, 12:44 PM

AN2 Therapeutics Cash Flow Statement

Table Mode

Year	FY23	FY22	FY21	FY20	FY19
Net Income	-64.73M	-40.96M	-21.54M	-13.6M	-5.63M
Depreciation & Amortization	n/a	-692K	n/a	n/a	n/a
Stock-Based Compensation	8.41M	4.39M	974K	40K	n/a
Other Working Capital	5.28M	1.22M	-385K	1.14M	6K
Other Non-Cash Items	-2.8M	77K	53K	6.97M	3.17M
Deferred Income Tax	n/a	n/a	n/a	n/a	n/a
Change in Working Capital	5.83M	3.72M	32K	1.22M	-10K
Operating Cash Flow	-53.29M	-33.46M	-20.48M	-5.36M	-2.49M
Capital Expenditures	n/a	n/a	n/a	n/a	n/a
Acquisitions	n/a	n/a	n/a	n/a	n/a
Purchase of Investments	-132.18M	-93.84M	-77.27M	n/a	n/a
Sales Maturities Of Investments	88.9M	72.06M	27.25M	n/a	n/a
Other Investing Acitivies	n/a	-21.77K	-50.02K	n/a	n/a
Investing Cash Flow	-43.28M	-21.77M	-50.02M	n/a	n/a
Debt Repayment	n/a	n/a	n/a	n/a	n/a
Common Stock Repurchased	n/a	-11K	n/a	n/a	n/a
Dividend Paid	n/a	n/a	n/a	n/a	n/a
Other Financial Acitivies	465K	-11K	78.53M	3.84M	48.5M
Financial Cash Flow	84.99M	70.36M	78.53M	3.84M	8.08M
Net Cash Flow	-11.57M	15.12M	8.03M	-1.53M	5.6M
Free Cash Flow	-53.29M	-33.46M	-20.48M	-5.36M	-2.49M